Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a dedicated Locations section listing Kansas and Pennsylvania sites and updated the page to revision v3.3.3.SummaryDifference0.3%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page revision from v3.2.0 to v3.3.2 did not change the study details or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedThe government funding lapse notice banner was removed from the page, eliminating the banner that previously warned about potential delays and operating status updates.SummaryDifference0.3%

- Check60 days agoChange DetectedNo significant additions or deletions detected; the study overview, eligibility criteria, and planned outcomes appear unchanged.SummaryDifference0.4%

- Check82 days agoChange Detected- Added a prominent funding/status notice and updated to revision v3.2.0. - Removed the previous revision reference v3.1.0.SummaryDifference3%

- Check90 days agoChange DetectedOverall, the page updates to a new revision (v3.1.0) with added contact details and identifiers; the previous revision v3.0.2 was removed.SummaryDifference0.1%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.